



ADULT Medication Monograph

MEDROXYPROGESTERONE

This document should be read in conjunction with this [DISCLAIMER](#)

[Formulary: Unrestricted](#)

Class	Progestogen
Presentation	Tablet: 5mg, 10mg, 100mg, 200mg Vial: 150mg/1mL
Storage	Store at room temperature, below 25°C
Dose	<p><u>Contraception</u> IM Injection: 150mg every 12 weeks</p> <p><u>Endometriosis</u> IM Injection: 150 mg every 12 weeks</p> <p>Oral: 10 mg 3 times daily</p> <p><u>Heavy Menstrual Bleeding (anovulatory)</u> Oral: 5–10 mg daily in 1 or 2 doses for 10–14 days during assumed second half of cycle</p> <p><u>Secondary Amenorrhoea</u> Oral: <i>Without estrogen</i> 2.5–10 mg once daily for 5–10 days during assumed second half of cycle Oral: <i>With estrogen</i> 5–10 mg once daily for 10 days.</p> <p><u>Management of Menopausal Symptoms:</u> Refer to Management of Menopause & Menopausal Symptoms</p>

<p>Administration</p>	<p><u>Oral:</u> Take with or without food</p> <p><u>IM:</u> Deep intramuscular injection into the gluteal or deltoid muscle. Shake injection before use.</p>
<p>Pregnancy</p>	<p>Medroxyprogesterone acetate (MPA) use during early pregnancy is not associated with an increase in non-genital malformations. There is conflicting evidence on whether hypospadias is associated with MPA use during pregnancy.</p> <p>Theoretically it could cause virilisation of female fetus if taken from 8 weeks after conception although this effect is unlikely as MPA is not a 19-nortestosterone derivative. This is a dose-dependent effect. Prior to 8 weeks post conception, they have no virilising effects</p> <p><u>IM (contraceptive dose) and Oral < 30mg daily:</u> 1st Trimester: Considered safe to use 2nd Trimester: Considered safe to use 3rd Trimester: Considered safe to use</p> <p><u>IM High dose and Oral > 30mg daily:</u> Seek more information from KEMH Obstetric Medicines Information Service.</p>
<p>Breastfeeding</p>	<p>Considered safe to use</p>
<p>Monitoring</p>	<p>Refer to clinical practice guidelines</p>
<p>Clinical Guidelines and Policies</p>	<p>KEMH Clinical Guidelines: Contraception: Post-Partum Contraception: Depot Medroxyprogesterone Acetate (DMPA) SHQ Contraception Injection Information for Patients Menopause & menopausal symptoms Gynaecology (Non-oncological): Endometriosis quick reference guide Menstrual bleeding: Heavy</p> <p>KEMH Pharmaceutical & Medicines Management Guidelines: KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration</p>
<p>References</p>	<p>Australian Medicines Handbook. Medroxyprogesterone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Feb</p>

27]. Available from: <https://amhonline.amh.net.au/>

Truven Health Analytics. Medroxyprogesterone. In: Micromedex [Internet]. Greenwood Village (CO): Truven Health Analytics; 2020 [cited 2020 May 13]. Available from: <http://www.micromedexsolutions.com/>

<https://www.tga.gov.au/node/4012>

The Royal Women's Hospital. Medroxyprogesterone In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2019 Feb 27]. Available from: <https://thewomenspbmg.org.au/>

Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. *Obstet Gynecol.* 1990;76(3 Pt 2):552-7.

Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. *Teratology.* 1988;38(2):135-44.

Society of Hospital Pharmacists of Australia. Medroxyprogesterone acetate. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Feb 27].

MIMS Australia. Medroxyprogesterone acetate. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2017 [cited 2020 Feb 27].

Keywords:	Medroxyprogesterone, Menopause, Contraception, Menstrual Disorder, HRT, Depo Ralovera, Depo Provera, DMPA		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	March 2015	Version:	4.0
Last reviewed:	July 2020	Next review date:	July 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	March 2015
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety		

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020